Immunogenicity of therapeutic proteins. Part 1: Impact of product handling

Biotechnology Advances

Volumn 25, Issue 3, 2007, Pages 310-317

  Sharma, Basant ^a  

^a Pharmaceutical Technology   (United States)

Author keywords

Biopharmaceutical; Biosimilar; Epoetin; Immunogenicity; Neutralizing antibody; PRCA; Therapeutic protein

Indexed keywords

BIOMATERIALS; IMMUNOLOGY; PHARMACODYNAMICS; QUALITY ASSURANCE;

BIOPHARMACEUTICAL; IMMUNOGENICITY; NEUTRALIZING ANTIBODY; THERAPEUTIC PROTEIN;

PROTEINS;

DRUG; RECOMBINANT PROTEIN;

ANTIBODY; DRUG DEVELOPMENT; HEMATOLOGY; IMMUNE RESPONSE; IMMUNITY; PHARMACEUTICAL INDUSTRY; PROTEIN;

HUMAN; IMMUNOLOGY; LABORATORY DIAGNOSIS; REVIEW; TEMPERATURE; TIME;

HUMANS; PHARMACEUTICAL PREPARATIONS; RECOMBINANT PROTEINS; SPECIMEN HANDLING; TEMPERATURE; TIME FACTORS;

EID: 33947710801     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2007.01.005     Document Type: Review

References (48)

1. Antonelli G., Giannelli G., Currenti M., Simeoni E., Del Vecchio S., Maggi F., et al. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy. Clin Exp Immunol 104 (1996) 384-387
2. Antonelli G., and Dianzani F. Development of antibodies to interferon beta in patients: technical and biological aspects. Eur Cytokine Netw 10 (1999) 413-422
3. Biotechnology Industry Organization. BIO comments to 2004N-0355: scientific considerations related to developing follow-on protein products (2004), BIO, Washington, DC. http://www.bio.org/reg/20041213.pdf Available at: http://www.bio.org/reg/20041213.pdf. Accessed November 16, 2005
4. Boven K., Stryker S., Knight J., Thomas A., van Regenmortel M., Kemeny D.M., et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 67 (2005) 2346-2353
5. Briet E., and Peters M. The incidence of inhibitors in hemophilia A and the induction of immune tolerance. Adv Exp Med Biol 489 (2001) 89-97
6. Casadevall N., Nataf J., Viron B., Kolta A., Kiladjian J.J., Martin-Dupont P., et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346 (2002) 469-475
7. Chance R.E., Root M.A., and Galloway J.A. The immunogenicity of insulin preparations. Acta Endocrinol Suppl (Copenh) 205 (1976) 185-198
8. Cleland J.L., Powell M.F., and Shire S.J. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carr Syst 10 (1993) 307-377
9. Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products (2005), European Medicines Agency, London. http://www.emea.eu.int/pdfs/human/biosimilar/043704en.pdf Available from: http://www.emea.eu.int/pdfs/human/biosimilar/043704en.pdf
10. Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (2006), European Medicines Agency, London. http://www.emea.eu.int/pdfs/human/biosimilar/4934805en.pdf Available from: http://www.emea.eu.int/pdfs/human/biosimilar/4934805en.pdf
11. Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (2006), London, European Medicines Agency. http://www.emea.eu.int/pdfs/human/biosimilar/4283205en.pdf Available from: http://www.emea.eu.int/pdfs/human/biosimilar/4283205en.pdf
12. Committee for Medicinal Products for Human Use. Guidance on similar medicinal products containing recombinant erythropoietins (2006), European Medicines Agency, London. http://www.emea.eu.int/pdfs/human/biosimilar/9452605en.pdf Available from: http://www.emea.eu.int/pdfs/human/biosimilar/9452605en.pdf
13. Committee for Medicinal Products for Human Use. Guidance on similar medicinal products containing somatropin (2006), European Medicines Agency, London. http://www.emea.eu.int/pdfs/human/biosimilar/9452805en.pdf Available from: http://www.emea.eu.int/pdfs/human/biosimilar/9452805en.pdf
14. Committee for Medicinal Products for Human Use. Guidance on similar medicinal products containing recombinant human soluble insulin (2006), European Medicines Agency, London. http://www.emea.eu.int/pdfs/human/biosimilar/3277505en.pdf Available from: http://www.emea.eu.int/pdfs/human/biosimilar/3277505en.pdf
15. Committee for Medicinal Products for Human Use. Guidance on similar medicinal products containing recombinant granulocyte-colony stimulating factor (2006), European Medicines Agency, London. http://www.emea.eu.int/pdfs/human/biosimilar/3132905en.pdf Available from: http://www.emea.eu.int/pdfs/human/biosimilar/3132905en.pdf
16. DePaolis A., Gunturi S., Wang J., Ghobrial I., and Sharma B. Product handling considerations: impact on immunogenicity. AAPS National Biotechnology Conference (2005) W3013
17. Fakharzadeh S.S., and Kazazian Jr. H.H. Correlation between factor VIII genotype and inhibitor development in hemophilia A. Semin Thromb Hemost 26 (2000) 167-171
18. Grauer A., Ziegler R., and Raue F. Clinical significance of antibodies against calcitonin. Exp Clin Endocrinol Diabetes 103 (1995) 345-351
19. Gregory R., Edwards S., and Yateman N.A. Demonstration of insulin transformation products in insulin vials by high-performance liquid chromatography. Diabetes Care 14 (1991) 42-48
20. Haselbeck A. Epoetins: differences and their relevance to immunogenicity. Curr Med Res Opin 19 (2003) 430-432
21. Hochuli E. Interferon immunogenicity: technical evaluation of interferon-alpha 2a. J Interferon Cytokine Res 17 Suppl 1 (1997) S15-S21
22. Jacquemin M.G., and Saint-Remy J.M. Factor VIII immunogenicity. Haemophilia 4 (1998) 552-557
23. Kontsek P., Liptakova H., and Kontsekova E. Immunogenicity of interferon-alpha 2 in therapy: structural and physiological aspects. Acta Virol 43 (1999) 63-70
24. Koren E., Zuckerman L.A., and Mire-Sluis A.R. Immune responses to therapeutic proteins in humans - clinical significance, assessment and prediction. Curr Pharm Biotechnol 3 (2002) 349-360
25. Kroon D.J., Baldwin-Ferro A., and Lalan P. Identification of sites of degradation in a therapeutic monoclonal antibody by peptide mapping. Pharm Res 9 (1992) 1386-1393
26. Lam X.M., Yang J.Y., and Cleland J.L. Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2. J Pharm Sci 86 (1997) 1250-1255
27. Lawley W.J., Fletcher S., Squire I.B., Woods K.L., and Hewitt C.R. T-cell recognition of discrete regions of the thrombolytic drug streptokinase. Clin Sci (Lond) 99 (2000) 239-246
28. Li S., Schöneich C., and Borchardt R.T. Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization. Biotechnol Bioeng 48 (1995) 490-500
29. Li J., Yang C., Xia Y., Bertino A., Glaspy J., Roberts M., et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98 (2001) 3241-3248
30. Lim L.C. Acquired red cell aplasia in association with the use of recombinant erythropoietin in chronic renal failure. Hematology 10 (2005) 255-259
31. Melian E.B., and Plosker G.L. Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C. Drugs 61 (2001) 1661-1691
32. Nihalani P., Agrawal M., and Anvekar A. Multi-source biopharmaceuticals: a new perspective. Clin Res Regul Aff 19 (2002) 367-380
33. Olsen E., Duvic M., Frankel A., Kim Y., Martin A., Vonderheid E., et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19 (2001) 376-388
34. Palleroni A.V., Aglione A., Labow M., Brunda M.J., Pestka S., Sinigaglia F., et al. Interferon immunogenicity: preclinical evaluation of interferon-alpha 2a. J Interferon Cytokine Res 17 Suppl 1 (1997) S23-S27
35. Peces R., de la Torre M., Alcazar R., and Urra J.M. Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N Engl J Med 335 (1996) 523-524
36. Pendley C., Schantz A., and Wagner C. Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther 5 (2003) 172-179
37. Prümmer O. Treatment-induced antibodies to interleukin-2. Biotherapy 10 (1997) 15-24
38. Ragnhammar P., and Wadhwa M. Neutralizing antibodies to granulocyte-macrophage colony stimulating factor (GM-CSF) in carcinoma patients following GM-CSF combination therapy. Med Oncol 13 (1996) 161-166
39. Rosenschein U., Lenz R., Radnay J., Ben Tovim T., and Rozenszajn L.A. Streptokinase immunogenicity in thrombolytic therapy for acute myocardial infarction. Isr J Med Sci 27 (1991) 541-545
40. Ryan M.H., Heavner G.A., Brigham-Burke M., McMahon F., Shanahan M.F., Gunturi S.R., et al. An in vivo model to assess factors that may stimulate the generation of an immune reaction to erythropoietin. Int Immunopharmacol 6 (2006) 647-655
41. Ryff J.C. Clinical investigation of the immunogenicity of interferon-alpha 2a. J Interferon Cytokine Res 17 Suppl 1 (1997) S29-S33
42. Ryff J.C., and Schellekens H. Immunogenicity of rDNA-derived pharmaceuticals. Trends Pharmacol Sci 23 (2002) 254-256
43. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 24 (2002) 1720-1740
44. Schellekens H. When biotech proteins go off-patent. Trends Biotechnol 22 (2004) 406-410
45. Schellekens H. Follow-on biologics: challenges of the 'next generation'. Nephrol Dial Transplant 20 Suppl 4 (2005) iv31-iv36
46. ®. Eur J Hosp Pharm 5 (2004) 86-91
47. Sorensen P.S., Ross C., Clemmesen K.M., Bendtzen K., Frederiksen J.L., Jensen K., et al. Clinical importance of neutralizing antibodies against interferon-beta in patients with relapsing-remitting multiple sclerosis. Lancet 362 (2003) 1184-1191
48. Zang Y.C., Yang D., Hong J., Tejada-Simon M.V., Rivera V.M., and Zhang J.Z. Immunoregulation and blocking antibodies induced by interferon beta treatment in MS. Neurology 55 (2000) 397-404